-+ 0.00%
-+ 0.00%
-+ 0.00%

ENANTA PHARMACEUTICALS - REGISTRATIONAL PHASE 2B/3 TRIAL IN HIGH-RISK ADULTS WITH RSV TO START Q4 2026; WITH TOPLINE PHASE 2B DATA EXPECTED IN 2027

Reuters·06/18/2026 11:00:00

Please log in to view news